Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry

INTRODUCTION: Guselkumab is approved for the treatment of both moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA) in the USA. However, little is known about patients initiating guselkumab in a real-world setting. The objective of this study was to describe baseline characterist...

Descripción completa

Detalles Bibliográficos
Autores principales: Walsh, Jessica A., Callis Duffin, Kristina, Van Voorhees, Abby S., Chakravarty, Soumya D., Fitzgerald, Timothy, Teeple, Amanda, Rowland, Katelyn, Uy, Jonathan, McLean, Robert R., Malley, Wendi, Cronin, Angel, Merola, Joseph F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776927/
https://www.ncbi.nlm.nih.gov/pubmed/34822121
http://dx.doi.org/10.1007/s13555-021-00637-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776927/
https://www.ncbi.nlm.nih.gov/pubmed/34822121
http://dx.doi.org/10.1007/s13555-021-00637-2

Ejemplares similares